MacroGenics, Inc. (MGNX)

US — Healthcare Sector

Peers: MOLN MLYS ANTX PHVS PEPG GLUE PMVP TYRA IPSC KZR NKTX NGM DAWN INZY ZNTL SNDX PTGX EWTX CCCC CGEM

Automate Your Wheel Strategy on MGNX

With Tiblio's Option Bot, you can configure your own wheel strategy including MGNX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol MGNX
Rev/Share 2.4208
Book/Share 1.2565
PB 1.154
Debt/Equity 0.4735
CurrentRatio 3.2844
ROIC -0.5699

MktCap 91480935.0
FreeCF/Share -1.1498
PFCF -1.2636
PE -1.6358
Debt/Assets 0.1668
DivYield 0
ROE -0.5984

Rating C
Score 2
Recommendation Sell
P/E Score 1
DCF Score 1
P/B Score 4
D/E Score 2

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
No ratings available.

News

4 Medical Product Stocks to Watch From a Challenging Industry

ALUR, CLRB, MGNX, PODD
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Negative

The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR reflect the favorable fundamentals.

image for news 4 Medical Product Stocks to Watch From a Challenging Industry

MacroGenics Announces Date of First Quarter 2025 Financial Results

MGNX
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral

ROCKVILLE, MD, May 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2025 after the market closes on Tuesday, May 13, 2025.

image for news MacroGenics Announces Date of First Quarter 2025 Financial Results

4 Medical Product Stocks to Buy From a Challenging Industry

ALUR, CLRB, MGNX, PODD
Published: April 17, 2025 by: Zacks Investment Research
Sentiment: Positive

The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR are likely to gain from the favorable factors.

image for news 4 Medical Product Stocks to Buy From a Challenging Industry

MacroGenics: Stacking Up A Lot Of Headwinds

MGNX
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral

MacroGenics' valuation has declined due to continued bad news in 2024, impacting market sentiment. MGNX holds $179.6M in cash and equivalents, with a sustainable cash burn rate for up to 5 years. Sale of the margetuximab franchise poises the company for further financial stability. Operating expenses are expected to rise as clinical programs advance, with management projecting a cash runway into 2026. I think this is a conservative estimate.

image for news MacroGenics: Stacking Up A Lot Of Headwinds

About MacroGenics, Inc. (MGNX)

IPO Date 2013-10-10
Website https://www.macrogenics.com
Industry Biotechnology
CEO Dr. Scott Koenig M.D., Ph.D.
Employees 341

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.